DIAPH2

Across TCGA pan-cancer cohorts, DIAPH2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of DIAPH2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where DIAPH2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types DIAPH2 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where DIAPH2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DIAPH2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	+0.797	<.001	12	view →
HNSC	Female	All	−0.743	<.001	11	view →
LSCC	Female	All	−0.814	<.001	9	view →
LUAD	Female	II,III,IV	−0.746	<.001	9	view →
COAD	All	II,III,IV	+0.116	<.001	8	view →
PDAC	Female	All	+0.190	.001	4	view →
OV	All	All	−0.390	.026	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

DIAPH2–CCRCC

Open the CCRCC breakdown →